*	Schering–Plough’s NDA approved December 1, 2009 (Schering-Plough HealthCare Products, Inc. is a division of Merck & Co., Inc.)
**	NDA approved December 4, 2009
***	GSK currently promotes Zegerid® Rx products in Puerto Rico and USVI. Regulatory submissions made in Latin America and Africa

Phase I clinical trials: The product is tested in a small number of patients or healthy volunteers, primarily for safety at one or more doses.

Phase II clinical trials: In addition to safety, the sponsor evaluates the efficacy of the products on targeted indications, and identifies possible adverse effects and safety risks, in a patient population somewhat larger than Phase I clinical trials.

Phase III clinical trials: These trials typically involve additional clinical evaluations of safety and clinical efficacy in an expanded population at geographically-dispersed test sites.

NDA (New Drug Application) is submitted to FDA or foreign regulatory authority for review and approval.

Marketed therapies are available in countries that have granted regulatory clearance.